I en undersøgelse designet til at vurdere seponeringssymptomer ved hjælp af Discontinuation Emergent Signs and Symptoms (DESS -) tjeklisten hos patienter med remitteret depression inducerede Valdoxan ikke seponeringssyndrom efter brat behandlingsstop.
In a study designed to assess discontinuation symptoms by the Discontinuation Emergent Signs and Symptoms (DESS) check-list in patients with remitted depression, Valdoxan did not induce discontinuation syndrome after abrupt treatment cessation.